In comparison to hematologic malignancies in which the KMT2A N-terminus is preserved, sarcomas with YAP::KMT2A and VIM::KMT2A rearrangement have KMT2A as the 3′ fusion partner (71). The gene discussed is KMT2A; the disease is hematologic disorder.